Vertex Hopes Two Cystic Fibrosis Drugs Better than One:
if !IE-->endif-->Content on this page requires a newer version of Adobe Flash Player.if !IE-->endif-->
CAMBRIDGE, Mass. (TheStreet) -- Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
Soon after Vertex reports first-quarter earnings, investor attention moves to two, more important events that will have a far greater influence on the future direction of the company's stock price: 1) The first look at the potency of two new hepatitis C drugs; and 2) results from a mid-stage "combo" study of Kalydeco and the experimental drug VX-809 in cystic fibrosis patients with the most commonly occurring (and therefore most commercially lucrative) genetic mutation F508del.
...
Click to view a price quote on VRTX.
Click to research the Drugs industry.
if !IE-->endif-->Content on this page requires a newer version of Adobe Flash Player.if !IE-->endif-->
CAMBRIDGE, Mass. (TheStreet) -- Vertex Pharmaceuticals is expected to report strong initial sales of its cystic fibrosis drug Kalydeco on Thursday as investors shift their attention away from the waning performance of the company's hepatitis C drug Incivek.
Soon after Vertex reports first-quarter earnings, investor attention moves to two, more important events that will have a far greater influence on the future direction of the company's stock price: 1) The first look at the potency of two new hepatitis C drugs; and 2) results from a mid-stage "combo" study of Kalydeco and the experimental drug VX-809 in cystic fibrosis patients with the most commonly occurring (and therefore most commercially lucrative) genetic mutation F508del.
...
Click to view a price quote on VRTX.
Click to research the Drugs industry.
Comments